Gastroenterology and Hepatology, University Hospital Leuven, 49 Herestraat, Leuven 3000, Belgium.
Gastroenterology and Hepatology, University Hospital Leuven, 49 Herestraat, Leuven 3000, Belgium.
Gastrointest Endosc Clin N Am. 2021 Jan;31(1):131-154. doi: 10.1016/j.giec.2020.09.004.
The treatment of early Barrett's esophagus (BE) has undergone a paradigm shift from surgical subtotal esophagectomy to organ-saving endoluminal treatment. Over the past 15 years, several high-quality studies were conducted to assess safe oncological outcome of endoscopic resection of mucosal adenocarcinoma and high-grade dysplasia. It became clear that add-on ablative therapy with radiofrequency ablation (RFA) significantly reduces recurrence risk of neoplasia after resection. In this review, we highlight the most essential elements to optimize outcomes of RFA of BE, addressing the correct indication and patient selection in combination with the most efficient and safest treatment protocols to obtain long-term durability.
早期 Barrett 食管 (BE) 的治疗已经从手术性食管大部切除术转变为器官保留的内镜治疗。在过去的 15 年中，进行了多项高质量的研究来评估内镜下切除黏膜腺癌和高级别异型增生的安全肿瘤学结果。很明显，射频消融 (RFA) 的附加消融治疗显著降低了切除后肿瘤复发的风险。在这篇综述中，我们强调了优化 RFA 治疗 BE 结果的最重要因素，包括正确的适应证和患者选择，以及最有效和最安全的治疗方案，以获得长期疗效。
